2023-08-23 12:03:27 ET
- Bavarian Nordic A/S press release ( OTCPK:BVNKF ): 1H net gain of DKK 914 million
- Revenue increased by 278% Y/Y to DKK 3,239 million.
For further details see:
Bavarian Nordic A/S reports 1H resultshome / stock / bvnkf / bvnkf news
2023-08-23 12:03:27 ET
For further details see:
Bavarian Nordic A/S reports 1H resultsMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Bavarian Nordic R/I Ord Company Name:
BVNKF Stock Symbol:
Market:
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in both the EU and in the U.S. COPENHAGEN, Denmark, June 26, 2024 – Bavarian Nordic ...
First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older Represents first BLA for a chikungunya vaccine for adolescents COPENHAGEN, Denmark, June 17, 2024...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for i...